Healthcare Global Enterprises · NSE: HCG · BSE: 539787

Q4 FY23 results · Jan–Mar 2023

Healthcare Global Enterprises reported revenue from operations of ₹441.71 crore (up 21.1% from Q4 FY22) and net profit of ₹5.65 crore (up 151.1% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY23	Q4 FY22	YoY	Q3 FY23	QoQ
Revenue from operations	441.71	364.63	+21.1%	424.68	+4.0%
Other income	4.65	3.01	+54.5%	3.65	+27.4%
Total income	446.36	367.64	+21.4%	428.33	+4.2%
Profit before share of associates & JVs and tax	13.14	0.92	14x	11.31	+16.2%
Share of profit/(loss) of associates & JVs	(0.01)	0.00		(0.01)
Net profit for the period	5.65	2.25	+151.1%	4.20	+34.5%
Attributable to shareholders of the company	8.37	5.99	+39.7%	7.54	+11.0%
EPS, basic (₹)	0.60	0.43	+39.5%	0.54	+11.1%
Net margin (%)	1.3	0.6		1.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY23	Q4 FY22	YoY	Q3 FY23	QoQ
Revenue from operations	258.67	220.19	+17.5%	252.68	+2.4%
Other income	3.56	2.25	+58.2%	2.10	+69.5%
Total income	262.23	222.44	+17.9%	254.78	+2.9%
Profit before tax	7.91	(15.73)	Turned profit	19.38	−59.2%
Net profit for the period	4.18	(17.92)	Turned profit	14.16	−70.5%
EPS, basic (₹)	0.30	(1.29)	Turned profit	1.02	−70.6%
Net margin (%)	1.6	-8.1		5.6

Consolidated

Filed with BSE: 25 May 2023, 20:37 IST
Board meeting: 25 May 2023
Period: 01 Jan 2023 to 31 Mar 2023
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 25 May 2023, 20:37 IST
Board meeting: 25 May 2023
Period: 01 Jan 2023 to 31 Mar 2023
Review status: Audited
Source: XBRL filing on BSE